New approach for mCRPC

New study results found that Cabozantinib plus Atezolizumab (C+A) can significantly

improve prognoses of patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed with prior novel hormonal therapy.

This phase 3 study, found that patients in the C+A group had longer radiographic progression-free survival (6.3 months) compared with the control group, though the group did experience more treatment-adverse events than the C+A group resulting in 16% of the control group discontinuing treatment versus 15 percent of the control group. The most common adverse effects include hypertension, anemia, diarrhea, and fatigue.

Oncology. February 1, 2024